Compare Amylx Pharmaceuticals Inc (AMLX) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Ecopetrol SA — how do they compare? Amylx Pharmaceuticals Inc trades at $17.17 (market cap $1.98B), while Ecopetrol SA trades at $15.97 (market cap $29.34B). The key difference: Ecopetrol SA is far larger — about 14.8× Amylx Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 4.17% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EC | |
|---|---|---|
Market Cap | $1.98B | $29.34B |
Sector | Health | Energy |
52-Week High | $18.70 | $16.58 |
52-Week Low | $7.64 | $8.29 |
Enterprise Value | $1.70B | $57.13B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Ecopetrol (EC) trades at $15.58, up 1.23% with bullish technical signals from moving averages. The stock shows mixed fundamentals with declining revenue from $159.6B in 2022 to $119.7B in 2025, though maintains stable 8.76% net margins. Recent corporate developments include a $0.66 dividend payment and S&P credit rating affirmation at BB- with stable outlook as of June 17, 2026.
EC presents a cautious opportunity with attractive valuation multiples (P/E 11.1, P/S 0.97) but faces revenue headwinds. Analyst consensus is mixed with 27% buy ratings and $14.63 target below current price. Key risks include energy price volatility and execution challenges amid declining cash flows from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
